Graham Dixon on Belinostat Plus CHOP in Patients With T-Cell Lymphoma

Graham Dixon, PhD, chief scientific officer, director of R&D, Onxeo, discusses a phase I study investigating the combination of belinostat (Beleodaq) plus CHOP in patients with peripheral T-cell lymphoma.

Belinostat is an HDAC inhibitor that was well tolerated in patients with peripheral T-cell lymphoma in the open-label, two-part study, Dixon explains, especially when combined with CHOP in the first-line setting. In this study, complete responses were reported in 67% of patients who received the combination. The overall response rate was 86%.

Dixon hopes additional studies will reflect these findings and lead to an expanded approval of belinostat in the first-line setting. The agent is currently approved by the FDA as a second-line treatment of relapsed/refractory peripheral T-cell lymphoma.